ଟେପଲିଜୁମାବ

ଟେପଲିଜୁମାବ
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	CD3
Clinical data
Trade names	Tzield
Synonyms	teplizumab-mzwv, PRV-031, MGA031
data	US DailyMed: Teplizumab;
Routes of; administration	Intravenous
Legal status
Legal status	US: ℞-only ;
Chemical and physical data
Formula	C6462H9938N1738O2022S46
Molar mass	୧,୪୫,୮୦୧.୪୯ g·mol−1
(verify)

ଟେପଲିଜୁମାବ, ଏକ ବେପାର ନାମ ଜିଏଲ୍ଡ (Tzield) ହେଉଛି ଏକ ଔଷଧ ଯାହା ପ୍ରାରମ୍ଭିକ ମଧୁମେହ ଟାଇପ ୧ରେ (ଆଇସଲେଟ୍ କୋଷରେ ଥିବା ଆଣ୍ଟିବଡି) ବ୍ୟବହୃତ ହୁଏ, କୌଣସି ଲକ୍ଷଣ ନ ଥିବା ଅସ୍ୱାଭାବିକ ରକ୍ତ ଶର୍କରା ସ୍ତର, ରୋଗ ଲକ୍ଷଣର ପ୍ରଗତି ହ୍ରାସ କରିବାକୁ ଦିଆଯାଏ ।^[୨] ^[୪] ଅତି କମରେ ୮ ବର୍ଷ ବୟସର ରୋଗୀଙ୍କ ନିମନ୍ତେ ଏହା ବ୍ୟବହୃତ ହୁଏ ।^[୨] ଏହା ଶିରାରେ ଧୀରେ ଧୀରେ ଇଞ୍ଜେକସନ ଆକାରରେ ଦିଆଯାଏ ।^[୨]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମୁଣ୍ଡବିନ୍ଧା, ରାସ ଏବଂ ସ୍ୱଳ୍ପ ଶ୍ୱେତ ରକ୍ତ କଣିକା ହୋଇପାରେ ।^[୨] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟା ମଧ୍ୟରେ ସାଇଟୋକାଇନ୍ ରିଲିଜ୍ ସିଣ୍ଡ୍ରୋମ, ସଂକ୍ରମଣ ଏବଂ ଆଲର୍ଜି ପ୍ରତିକ୍ରିୟା ହୋଇପାରେ ।^[୨] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।^[୨] ଏହା ଏକ ମୋନୋକ୍ଲୋନାଲ ଆଣ୍ଟିବଡି ଯାହାଟି ଲିମ୍ଫୋସାଇଟରେ ଥିବା ସିଡି୩କୁ (CD3) ଅବରୋଧ କରିଥାଏ ।^[୨] ବିଶ୍ୱାସ କରାଯାଏ ଯେ ଏହା ପାନକ୍ରିଆସ୍ ବିଟା କୋଷର ଆକ୍ରମଣ ହ୍ରାସ କରିଥାଏ।^[୨]

୨୦୨୨ରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା ବ୍ୟବହାର ପାଇଁ ଟେପଲିଜୁମାବ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୨] ୨୦୨୨ ମସିହା ସୁଦ୍ଧା ଏହା ୟୁରୋପ କିମ୍ବା ବ୍ରିଟେନରେ ଅନୁମୋଦିତ ହୋଇନାହିଁ ।^[୫] ଦୁଇ ସପ୍ତାହ ଚିକିତ୍ସା ଖର୍ଚ୍ଚ ୨୦୨୨ ସୁଦ୍ଧା ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ପ୍ରାୟ ୨୦୦,୦୦୦ ଡଲାର ଥିଲା ।^[୬]

ଆଧାର

↑ "Provention Bio Announces PRV-031 (Teplizumab) Granted PRIME Designation by the European Medicines Agency" (Press release). Provention Bio. 24 October 2019. Archived from the original on 18 November 2022. Retrieved 18 November 2022 – via PR Newswire.
↑ ^୨.୦୦ ^୨.୦୧ ^୨.୦୨ ^୨.୦୩ ^୨.୦୪ ^୨.୦୫ ^୨.୦୬ ^୨.୦୭ ^୨.୦୮ ^୨.୦୯ "Tzield- teplizumab-mzwv injection". DailyMed. 17 November 2022. Archived from the original on 4 December 2022. Retrieved 4 December 2022.
↑ "FDA Approves First Drug That Can Delay Onset of Type 1 Diabetes". U.S. Food and Drug Administration (Press release). 17 November 2022. Archived from the original on 16 December 2022. Retrieved 18 November 2022. This article incorporates text from this source, which is in the public domain.
↑ American Diabetes Association Professional Practice Committee (1 January 2022). "2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022". Diabetes Care. 45 (45): S17–S38. doi:10.2337/dc22-S002. PMID 34964875. Archived from the original on 18 November 2022. Retrieved 17 November 2022.
↑ "Teplizumab". SPS - Specialist Pharmacy Service. 29 April 2019. Archived from the original on 30 November 2021. Retrieved 16 December 2022.
↑ "FDA approves 1st drug to delay the onset of Type 1 diabetes". NBC News (in ଇଂରାଜୀ). Archived from the original on 15 December 2022. Retrieved 16 December 2022.

[prv031-1] "Provention Bio Announces PRV-031 (Teplizumab) Granted PRIME Designation by the European Medicines Agency" (Press release). Provention Bio. 24 October 2019. Archived from the original on 18 November 2022. Retrieved 18 November 2022 – via PR Newswire.

[PI2022-2] ୨.୦୦ ^୨.୦୧ ^୨.୦୨ ^୨.୦୩ ^୨.୦୪ ^୨.୦୫ ^୨.୦୬ ^୨.୦୭ ^୨.୦୮ ^୨.୦୯ "Tzield- teplizumab-mzwv injection". DailyMed. 17 November 2022. Archived from the original on 4 December 2022. Retrieved 4 December 2022.

[FDA_PR-3] "FDA Approves First Drug That Can Delay Onset of Type 1 Diabetes". U.S. Food and Drug Administration (Press release). 17 November 2022. Archived from the original on 16 December 2022. Retrieved 18 November 2022. This article incorporates text from this source, which is in the public domain.

[Stages2022-4] American Diabetes Association Professional Practice Committee (1 January 2022). "2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022". Diabetes Care. 45 (45): S17–S38. doi:10.2337/dc22-S002. PMID 34964875. Archived from the original on 18 November 2022. Retrieved 17 November 2022.

[5] "Teplizumab". SPS - Specialist Pharmacy Service. 29 April 2019. Archived from the original on 30 November 2021. Retrieved 16 December 2022.

[6] "FDA approves 1st drug to delay the onset of Type 1 diabetes". NBC News (in ଇଂରାଜୀ). Archived from the original on 15 December 2022. Retrieved 16 December 2022.

[୨]

[୪]

[୧]

[୩]

[୫]

[୬]